At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 165 enrolled
Drug / intervention
Oleogel-S10 100 mg/g +1 moredrug
Likely dose
Oleogel-S10 100 mg/gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Multicenter, Double Blind Study to Compare the Efficacy and Tolerability of Oleogel-S-10 for 3 Month Versus Placebo Only in Patients With Mild to Moderate Actinic Keratoses Located at the Face and Head Oleogel-S-10 in Actinic Keratoses Trial
In Brief
A Phase 2 clinical trial evaluating Oleogel-S10 100 mg/g and Placebo (petroleum jelly) for Actinic Keratoses. Completed, enrolled 165 participants across 6 sites in 2 countries.
Detailed Summary
In this study the impact of Oleogel-S-10 versus placebo on actinic keratoses over a treatment period of 3 months will be tested. Additionally, once and twice daily applications are tested.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsActinic Keratoses
CountriesGermany, Greece
CollaboratorsUniversity Hospital Tuebingen
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2008
First PostedNov 2008
Primary CompletionNov 2010
TodayJul 2026
First PostedNov 6, 2008
Enrollment StartOct 1, 2008
Primary CompletionNov 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 17.7 years ago
Interventions
Oleogel-S10 100 mg/gdrug
topical use once or twice daily
Placebo (petroleum jelly)drug
topical use once or twice daily